الفهرس 
Introduction & Aim of the workOnly 14 pages are availabe for public view
 |  | from | 139 |  |  |
| | | from | 139 | | |
Abstract
Introduction:Hepatitis C virus infection is a global Health challenge, leads to increase in morbidities and deaths not only from chronic Liver disease and its complications such as cirrhosis, liver cell failure and HCC, but also extra-hepatic diseases. Presence of certain Polymorphisms close to gene of the IL-28B which display potent antiviral activity, were demonstrated at higher frequencies in persons who spontaneously cleared the HCV infection or who responded to PEG-IFN/ RBV treatment and may modify the course of infection. Aim of the study: Is to determine the association of a SNP, rs 12979860 of the IL-28B gene with response to therapy by Sofosbuvir+ Ribavirin ± Interferon in Egyptian Patients with chronic hepatitis C infection.Plane and methods: The rs 12979860 SNP of IL-28B gene was determined by PCR-RFLP assay from extracted Genomic DNA from whole blood samples withdrawn from 200 CHC adult Egyptian patients subjected to HCV therapy at Tropical Department Outpatient Clinic, Mansoura University Hospital. 114 patients received dual therapy for 6 months and 86 patients received triple therapy for 3 months. Each group was subdivided according to response to the given therapy into responders (SVR), and Non responders (non SVR).Results: The CC Genotype and C Allele of IL-28B rs12979860 were significantly associated with SVR in both dual and triple therapy groups, but TT Genotype & T allele were significantly associated with failure to achieve SVR (non SVR) in both therapy groups. Conclusion: IL-28B rs12979860 CC genotype and C allele could be considered as predictors of response to Sofosbuvir based HCV treatment, while the TT genotype was a risk factor for treatment failure (non SVR).